scholarly journals Boron Neutron Capture Therapy: A Review of Clinical Applications

2021 ◽  
Vol 11 ◽  
Author(s):  
Timothy D. Malouff ◽  
Danushka S. Seneviratne ◽  
Daniel K. Ebner ◽  
William C. Stross ◽  
Mark R. Waddle ◽  
...  
Keyword(s):  
Alpha Particle ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Breast Cancers ◽  
Lung Cancers ◽  
Normal Tissues ◽  
Boron Neutron Capture ◽  
Pediatric Cancers ◽  
Tumor Tissues

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget’s disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

Boron Neutron Capture Therapy: Cellular Targeting of High Linear Energy Transfer Radiation

2003 ◽  
Vol 2 (5) ◽  
pp. 355-375 ◽  
Author(s):  
Jeffrey A. Coderre ◽  
Julie C. Turcotte ◽  
Kent J. Riley ◽  
Peter J. Binns ◽  
Otto K. Harling ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Analytical Techniques ◽  
Neutron Capture Therapy ◽  
Normal Brain ◽  
Normal Tissues ◽  
Boron Neutron Capture ◽  
Subsequent Activation ◽  
The Individual

Boron neutron capture therapy (BNCT) is based on the preferential targeting of tumor cells with10 B and subsequent activation with thermal neutrons to produce a highly localized radiation. In theory, it is possible to selectively irradiate a tumor and the associated infiltrating tumor cells with large single doses of high-LET radiation while sparing the adjacent normal tissues. The mixture of high- and low-LET dose components created in tissue during neutron irradiation complicates the radiobiology of BNCT. Much of the complexity has been unravelled through a combination of preclinical experimentation and clinical dose escalation experience. Over 350 patients have been treated in a number of different facilities worldwide. The accumulated clinical experience has demonstrated that BNCT can be delivered safely but is still defining the limits of normal brain tolerance. Several independent BNCT clinical protocols have demonstrated that BNCT can produce median survivals in patients with glioblastoma that appear to be equivalent to conventional photon therapy. This review describes the individual components and methodologies required for effect BNCT: the boron delivery agents; the analytical techniques; the neutron beams; the dosimetry and radiation biology measurements; and how these components have been integrated into a series of clinical studies. The single greatest weakness of BNCT at the present time is non-uniform delivery of boron into all tumor cells. Future improvements in BNCT effectiveness will come from improved boron delivery agents, improved boron administration protocols, or through combination of BNCT with other modalites.

scholarly journals Development of an Imaging Technique for Boron Neutron Capture Therapy

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 2135
Author(s):  
Nobuyoshi Fukumitsu ◽  
Yoshitaka Matsumoto
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Animal Studies ◽  
Imaging Technique ◽  
Clinical Settings ◽  
Neutron Capture Therapy ◽  
Normal Tissues ◽  
Dose Prediction ◽  
Boron Neutron Capture ◽  
Positron Emission

The development of 4-10B-borono-2-18F-fluoro-L-phenylalanine (18FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). 18FBPA has shown similar pharmacokinetics and distribution to 4-10B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. 18FBPA PET is useful for treatment indication. A higher 18FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, 18FBPA PET is useful for predicting the 10B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using 18FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of 18FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of 18FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and 10B is also in progress.

scholarly journals A Novel Boron Lipid to Modify Liposomal Surfaces for Boron Neutron Capture Therapy

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3421
Author(s):  
Makoto Shirakawa ◽  
Alexander Zaboronok ◽  
Kei Nakai ◽  
Yuhki Sato ◽  
Sho Kayaki ◽  
...  
Keyword(s):  
Aqueous Phase ◽  
Anticancer Agents ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Bilayer Membrane ◽  
Molar Ratio ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Tumor Tissues ◽  
Constant Molar Ratio

Boron neutron capture therapy (BNCT) is a cancer treatment with clinically demonstrated efficacy using boronophenylalanine (BPA) and sodium mercaptododecaborate (BSH). However, tumor tissue selectivity of BSH and retention of BPA in tumor cells is a constant problem. To ensure boron accumulation and retention in tumor tissues, we designed a novel polyethylene glycol (PEG)-based boron-containing lipid (PBL) and examined the potency of delivery of boron using novel PBL-containing liposomes, facilitated by the enhanced permeability and retention (EPR) effect. PBL was synthesized by the reaction of distearoylphosphoethanolamine and BSH linked by PEG with Michael addition while liposomes modified using PBL were prepared from the mixed lipid at a constant molar ratio. In this manner, novel boron liposomes featuring BSH in the liposomal surfaces, instead of being encapsulated in the inner aqueous phase or incorporated in the lipid bilayer membrane, were prepared. These PBL liposomes also carry additional payload capacity for more boron compounds (or anticancer agents) in their inner aqueous phase. The findings demonstrated that PBL liposomes are promising candidates to effect suitable boron accumulation for BNCT.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18F]FBPA using aryldiboron precursors

2021 ◽  
Author(s):  
Jing He ◽  
Heng Yan ◽  
Yanrong Du ◽  
Yan Ji ◽  
Fei Cai ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

A reliable copper-mediated nucleophilic radiosynthesis of the BNCT-oriented PET probe [18F]FBPA was developed using novel aryldiboron precursors.

scholarly journals Optimized beam shaping assembly for a 2.1-MeV proton-accelerator-based neutron source for boron neutron capture therapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pablo Torres-Sánchez ◽  
Ignacio Porras ◽  
Nataliya Ramos-Chernenko ◽  
Fernando Arias de Saavedra ◽  
Javier Praena
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Beam Shaping ◽  
Proton Accelerator ◽  
Neutron Capture Therapy ◽  
Beam Shape ◽  
New Era ◽  
Boron Neutron Capture ◽  
Optimal Beam ◽  
Beam Shaping Assembly

AbstractBoron Neutron Capture Therapy (BNCT) is facing a new era where different projects based on accelerators instead of reactors are under development. The new facilities can be placed at hospitals and will increase the number of clinical trials. The therapeutic effect of BNCT can be improved if a optimized epithermal neutron spectrum is obtained, for which the beam shape assembly is a key ingredient. In this paper we propose an optimal beam shaping assembly suited for an affordable low energy accelerator. The beam obtained with the device proposed accomplishes all the IAEA recommendations for proton energies between 2.0 and 2.1 MeV. In addition, there is an overall improvement of the figures of merit with respect to BNCT facilities and previous proposals of new accelerator-based facilities.

Sign in / Sign up

Export Citation Format

Share Document